UDP-glucuronate decarboxylase 1 promotes tumor immune evasion by accelerating KMT2D loss in hepatocellular carcinoma
A newly discovered tumor immune escape pathway combines with checkpoint inhibitors to control liver cancer in experimental models.
This study defines a novel UXS1-FBXW7-KMT2D-CEBPB-PD-L1 signaling cascade whereby the glycosyltransferase UXS1 (upregulated by copy number gain and promoter demethylation in HCC) promotes immune evasion by degrading the epigenetic tumor suppressor KMT2D, which normally scaffolds CEBPB at the PD-L1 promoter to maintain its silencing. UXS1 knockout combined with anti-PD-1 therapy showed synergistic tumor control in vivo, nominating this axis as a resistance mechanism targetable to enhance HCC immunotherapy efficacy.
What the study was
- Study design
- experimental_preclinical_mechanistic
- Category
- novel_therapeutics
- Maturity
- Exploratory
- Journal
- J Immunother Cancer
Why it surfaced
Mechanistically novel and well-validated immune evasion pathway in HCC using multi-omics approaches; in vivo anti-PD-1 synergy is directly actionable; addresses the major clinical challenge of HCC immunotherapy resistance; J Immunother Cancer quality.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.